Trimb Healthcare (“Trimb”) has completed the acquisition of BioClin BV (“BioClin”), a leading intimate healthcare company based in Delft, Netherlands.
Magnus Nylén takes over as CEO
You’ve been the CEO since June; tell us about it.
I assumed the position of CEO at Trimb in the middle of June, just as we completed the acquisition of Pevaryl and Fungoral from J&J. For us at Trimb the Pevaryl/Fungoral acquisition is an important step in our journey towards becoming established as a leading OTC company on the European market. The acquisition provides us with the opportunity to be more aggressive in our direct markets (Nordic region, UK and Netherlands) regarding organic growth, as well as the opportunity to carry out future acquisitions that are in line with our growth strategy.
Tell us about your background.
Throughout my working life I’ve been active in the life sciences, both in Specialty Pharma and in consumer health, exclusively in commercial roles, including business development. My last position was at Exeltis, a company within the Spanish pharmaceutical group Chemo. I launched the company in the Nordic countries and I was responsible for the company in the Baltic region. Before that I built up the self-care business at Actavis on both a national and regional level. It was a fabulous success story that lasted almost 10 years.
How would you describe yourself as a leader?
I believe in an open and informal approach to leadership, where the team takes centre stage. Like any competition-driven executive, I want my leadership to be a source of energy and focus in the organization, setting clear goals and visions that we will make every effort to work together to achieve. There is nothing better than a shared victory.
Trimb Healthcare AB (“Trimb”) has entered into a definitive agreement with CCS Healthcare Nordic AB (“CCS”) to acquire their portfolio of skin care products in Sweden, Norway and the UK (“CCS Skinc
On 28 June Trimb Healthcare AB completed the acquisition of a portfolio of well-established European OTC products from Cilag GmbH International and Janssen Pharmaceutica NV (collectively, “J&J”